Data Shows Americans Hold Similar Views of Drugmakers, PBMs

Drugmakers have pointed to pharmacy benefit managers as a force behind rising drug prices in the U.S., but Americans don’t appear to have a gloomier view of one industry group over the other, according to Morning Consult Brand Intelligence data.

U.S. adults don’t have significantly higher favorability rates for certain pharmaceutical and biotechnology companies as opposed to pharmacies, suppliers and pharmacy benefit managers, according to surveys of more than 22,000 American adults from October to March.

For companies in both categories, companies with higher brand identification have higher positive favorability, meaning that better-known drug companies are likely to have higher approval ratings.

For example, New Jersey-based Johnson & Johnson has the highest brand identification among companies tracked by Morning Consult, with 97 percent of adults being aware of the company, and 72 percent of adults having a favorable view of the manufacturer. From the other side, AbbVie, a relatively new spinoff of Abbott Laboratories, is known by 33 percent of respondents and has 80 percent neutral favorability, while Gilead’s brand identification is 39 percent, with 76 percent of Americans holding a neutral view of the pharmaceutical company.

Pfizer and Bristol-Myers Squibb appear to be more controversial. Pfizer, which called off an attempted $160 billion takeover of Allergan last year after the Treasury Department altered a rule around so-called tax inversions, has an 86 percent brand identification, with a 35 percent positive favorability and a 28 percent negative favorability, the highest among pharmaceutical brands tracked. And 79 percent of people have heard of pharma company Bristol-Myers Squibb, which has 38 percent positive favorability and an 18 percent negative favorability.

But every pharmaceutical company tracked has a higher positive favorability than negative favorability, despite some companies coming under fire in recent years for the rising prices of prescription drugs. A June 2015 Kaiser Family Foundation poll found 77 percent of Americans said pharmaceutical profits were a major factor contributing to drug prices, while a Kaiser poll in September found a similar percentage said the drug costs were unreasonable. On the other hand, 73 percent of people currently taking a prescription drug told Kaiser affording their treatment is easy.

In recent months, some pharmaceutical executives have sought to shift the blame for rising drug costs to pharmacy benefit managers and other middlemen.

Mylan CEO Heather Bresch, who was scrutinized last year for the high price of EpiPens, told CNBC in January that the country’s pharmaceutical distribution system enables different entities to make a profit off such treatments, and greater use of high-deductible insurance plans has also shifted more costs to patients. A Gilead Sciences executive told Bloomberg last week that the company can’t lower the cost of its hepatitis C treatments because pharmacy benefit managers wouldn’t cover them.

PBMs, who serve as a middleman between employers and health plans and drugmakers, say they help lower drug costs for consumers. The Pharmaceutical Care Management Association, a trade group representing PBMs, touts that they will save payers and patients an estimated $250 billion over the next 10 years.

Three large pharmacies – Walgreens, CVS Health and Rite Aid – all have brand identification ratings above 90 percent, and positive favorability ratings of 79 percent, 68 percent and 64 percent, respectively, according to the Morning Consult data. Some pharmacies partner with specific PBMs: Walgreens announced a partnership with Prime Therapeutics last year and CVS works with CVS Caremark.

Express Scripts, one of the larger pharmacy benefit managers in the U.S., is known among 57 percent of Americans, and 29 percent view it favorably; another 61 percent have a neutral view of the firm. Its negative favorability – 10 percent – is similar to ratings for other pharmacies.

 

Correction: A previous version of this story incorrectly stated the date for the first Kaiser Foundation poll. It was conducted in June 2015.

Briefings

Health Brief: GOP Senators Ask CBO to Fast-Track ACA Overhaul Review

Senate Republican leaders have asked the Congressional Budget Office to fast-track consideration of a plan from Sens. Lindsey Graham (R-S.C.) and Bill Cassidy (R-La.) to overhaul the Affordable Care Act. The CBO is reportedly in the process of analyzing the cost and coverage impact of the plan, as Republicans face pressure to make one last attempt at undoing the ACA before GOP senators’ ability to pass legislation with a simple majority expires on Sept. 30.

Health Brief: Week in Review & What’s Ahead

HELP Committee Chairman Lamar Alexander (R-Tenn.) hopes to reach a deal with Democrats on a plan to shore up the ACA exchanges early this week. A final agreement, if reached, is likely to extend key insurer payments, known as cost-sharing reductions, and include reforms to make it easier for states to establish reinsurance programs. Some Republicans are also pushing to give states more flexibility over required benefits in Obamacare plans, a proposal that is controversial with Democrats.

Health Brief: Some Moderate House Democrats Seek ACA Stabilization

While progressives this week rallied behind Sen. Bernie Sanders’ (I-Vt.) single-payer health care bill, a group of moderate House Democrats in the New Democrat Coalition aligned themselves with the Senate Health, Education, Labor and Pensions Committee’s bipartisan push to stabilize the Affordable Care Act exchanges, which Committee Chairman Lamar Alexander (R-Tenn.) aims to reach a final deal on by early next week.

Health Brief: Deal Reached to Extend CHIP Funding

Senate Finance Committee leaders reached a deal on a five-year reauthorization of the Children’s Health Insurance Program, in a win for children’s health advocates who are seeking longer-term funding certainty for the program, which will expire at the end of the month without congressional action. The deal also gradually phases out the enhanced federal share of funding for state CHIP programs, which was increased under the Affordable Care Act by 23 percentage points.

Health Brief: Some Navigators Shut Down Ahead of ACA Enrollment Period

Several navigator organizations, including one that received the largest federal grant for Obamacare enrollment activities in 2016, are suspending operations ahead of the 2018 open enrollment season because they haven’t received contracts for funding from the Department of Health and Human Services, which could cause enrollment to plummet. The Trump administration announced plans last month to cut funding for navigator groups by about 40 percent, but health officials haven’t said whether the grants would end altogether.

Health Brief: Teva Names New CEO

H. Lundbeck A/S’s Kaare Schultz was named as Teva Pharmaceutical Industries Ltd.’s new chief executive officer, ending a seven-month search by the world’s largest generic drug maker to find a new leader. Schultz could face pressure to split the company into two businesses, one focusing on patented specialty drugs and the other on cheap copycat medicines

Health Brief: Week in Review & What’s Ahead

HELP Committee Chairman Alexander hopes to reach bipartisan consensus on a bill to shore up the ACA exchanges by the end of the week. The committee is set to hold two final hearings as members try to resolve two issues: the duration of funding for insurer payments known as cost-sharing reductions and the best way to approach reinsurance.

Load More